Correction
Published on 27 Aug 2025
Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
in Cancer Immunity and Immunotherapy
- 219 views